TeliMET NSCLC-01
The confirmatory trial for the first c-MET ADC, which was approved early on response rate alone.
Randomised phase 3 to confirm the May 2025 accelerated approval (LUMINOSITY ORR ~35% in c-Met high). Enrolment ongoing.
Setting
Previously treated c-Met-overexpressing, EGFR-wild-type non-squamous NSCLC: telisotuzumab vedotin vs docetaxel
Phase
Phase 3
Sponsor
AbbVie
Registry
Enrolled
698
Replication
Ongoing confirmatory trial for the LUMINOSITY-based accelerated approval.
Pages like this
not linked directly; found by shared links- TermMET amplification (bypass resistance)
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
- PersonJürgen Wolf
Shares MET, Non-small-cell lung cancer.
- ProductCapmatinib & tepotinib
Shares MET, Non-small-cell lung cancer.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares MET, Non-small-cell lung cancer.
- PersonDae Ho Lee
Shares MET, Non-small-cell lung cancer.
- ProductTilatamig samrotecan
Shares MET, Non-small-cell lung cancer.
- PersonKoichi Goto
Shares MET, Non-small-cell lung cancer.
- PairingAmivantamab + lazertinib (first-line EGFR NSCLC)
Shares MET, Non-small-cell lung cancer.